Corticosteroids Versus Cyclosporine for Subepithelial Infiltrates Secondary to Epidemic Keratoconjunctivitis: A Prospective Randomized Double-Blind Study
- PMID: 33201059
- DOI: 10.1097/ICO.0000000000002589
Corticosteroids Versus Cyclosporine for Subepithelial Infiltrates Secondary to Epidemic Keratoconjunctivitis: A Prospective Randomized Double-Blind Study
Abstract
Purpose: To compare efficiency and tolerance between topical 0.5% cyclosporine A (CSA) and fluorometholone (FML) for subepithelial infiltrates (SEI) complicating epidemic keratoconjunctivitis.
Methods: We conducted a prospective double-blind randomized study involving 72 eyes with SEI. Thirty-eight eyes were treated with topical FML (FML group) and 34 eyes with CSA 0.5% eye drops (CSA group). Treatment was considered successful in case of SEI reduction and visual acuity improvement. Tolerance was evaluated by Schirmer test value, burning on eye drops instillation, and conjunctival injection.
Results: Baseline characteristics of both groups were similar (P > 0.05). After 3 months of the regimen, resolution of SEI was 3 times more observed in the FML group than that in the CSA group (P = 0.026). After 6 months, resolution of SEI was observed in 70% of the FML group and in 47% of the CSA group (P = 0.068). The recurrence of SEI was almost twice higher in the FML group than that in the CSA group (16% vs. 9%). FML was better tolerated during the first 3 months: a higher Schirmer test value (P = 0.0003), less burning on instillation (P = 0.242), and less conjunctival injection (P = 0.003). For the rest of the follow-up period, the 2 groups were comparable in tolerance. No ocular hypertension was noted.
Conclusions: Epidemic keratoconjunctivitis can evolve favorably under both FML and CSA. The effect of FML is faster and CSA is more durable with fewer recurrences. Both are safe therapeutic options for long-term control of SEI.
Trial registration: ClinicalTrials.gov NCT04376970.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors have no funding or conflicts of interest to disclose.
Similar articles
-
Comparison of therapeutic effects of 0.05% Cyclosporine A versus 0.1% Fluorometholone in Chinese patients with mild dry eye unresponsive to artificial tears: a randomized control study.BMC Ophthalmol. 2024 Nov 27;24(1):513. doi: 10.1186/s12886-024-03771-5. BMC Ophthalmol. 2024. PMID: 39604906 Free PMC article. Clinical Trial.
-
Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis.BMC Ophthalmol. 2012 Aug 18;12:42. doi: 10.1186/1471-2415-12-42. BMC Ophthalmol. 2012. PMID: 22900547 Free PMC article. Clinical Trial.
-
Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis.Cornea. 2011 Sep;30(9):958-61. doi: 10.1097/ICO.0b013e31820cd607. Cornea. 2011. PMID: 21673568
-
Topical cyclosporine A 1 mg/ml for atopic keratoconjunctivitis: Five-year case series of 99 children and young people.Acta Ophthalmol. 2023 Mar;101(2):e197-e204. doi: 10.1111/aos.15251. Epub 2022 Sep 23. Acta Ophthalmol. 2023. PMID: 36151755 Review.
-
Do reducing regimens of fluorometholone for paediatric ocular surface disease cause glaucoma?Br J Ophthalmol. 2011 Nov;95(11):1531-3. doi: 10.1136/bjo.2010.192773. Epub 2011 Feb 4. Br J Ophthalmol. 2011. PMID: 21296793 Review.
Cited by
-
Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis.Cochrane Database Syst Rev. 2022 Mar 3;3(3):CD013520. doi: 10.1002/14651858.CD013520.pub2. Cochrane Database Syst Rev. 2022. PMID: 35238405 Free PMC article.
-
Comparison of the Effect of and Compliance With Cyclosporine 0.1% After Various Pretreatments in Dry Eye Disease.J Ophthalmol. 2025 Jan 7;2025:6744482. doi: 10.1155/joph/6744482. eCollection 2025. J Ophthalmol. 2025. PMID: 39816208 Free PMC article.
-
Topical Pharmacologic Interventions Versus Active Control, Placebo, or No Treatment for Epidemic Keratoconjunctivitis: Findings From a Cochrane Systematic Review.Am J Ophthalmol. 2022 Aug;240:265-275. doi: 10.1016/j.ajo.2022.03.018. Epub 2022 Mar 22. Am J Ophthalmol. 2022. PMID: 35331686 Free PMC article.
-
Evaluating anterior corneal surface using Placido ring mires for irregular astigmatism in refractory corneal subepithelial infiltrates after adenoviral conjunctivitis.BMC Ophthalmol. 2024 Nov 28;24(1):515. doi: 10.1186/s12886-024-03774-2. BMC Ophthalmol. 2024. PMID: 39609742 Free PMC article.
-
Steroids in the Management of Infectious Keratitis.Cornea. 2023 Nov 1;42(11):1333-1339. doi: 10.1097/ICO.0000000000003340. Epub 2023 Jul 4. Cornea. 2023. PMID: 38112645 Free PMC article. Review.
References
-
- Jhanji V, Chan TCY, Li EYM, et al. Adenoviral keratoconjunctivitis. Surv Ophthalmol. 2015;60:435–443.
-
- Hillenkamp J, Sundmacher R, Reinhard T. Treatment of adenoviral keratoconjunctivitis. In: Reinhard T, ed. Cornea and External Eye Disease. Berlin, Heidelberg: Springer Berlin Heidelberg; 2006:163–172.
-
- Renard G. Adenoviral keratoconjunctivitis [in French]. J Fr Ophtalmol. 2010;33:586–592.
-
- Jeng BH, Holsclaw DS. Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis. Cornea. 2011;30:958–961.
-
- Levinger E, Trivizki O, Shachar Y, et al. Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2014;252:811–816.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical